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O n December 1, 2006, a Morbidity and Mortality Weekly Report (MMWR) was published outlining 
General Recommendations on 
immunizations.   
The new recommendations provide technical 
guidance about common vaccination 
concerns for clinicians and other health-care 
providers who administer vaccines to infants, 
children, adolescents, and adults.   
Standards for child and adolescent 
vaccination practices and standards for adult 
vaccination practices have been published to 
assist with implementing vaccination 
programs and maximizing their benefits.  
Any person or institution that provides 
vaccination services should adopt these 
standards to improve vaccination 
delivery and protect patients from 
vaccine-preventable diseases. 
A brief summary of changes to the 
General Recommendations on 
Immunization include:   
• Expansion of the discussion of  
vaccination spacing and timing  
• Increased emphasis on the 
importance of injection 
techniques/ age/ body mass in 
determining appropriate needle 
length 
• Expansion of the discussion of 
storage and handling of 
vaccines, with a table defining 
the appropriate storage temperature 
range for inactivated and live vaccines 
• Expansion of the discussion regarding 
altered immunocompetence, including 
new recommendations about use of live-
attenuated vaccines with therapeutic 
monoclonal antibodies 
• Minor changes to the recommendations 
about vaccination during pregnancy and 
vaccination of internationally adopted 
children, in accordance with new 
Advisory Committee on Immunization 
Practices (ACIP) vaccine-specific 
recommendations for use of inactivated 
influenza vaccine and hepatitis B 
vaccine. 
The General Recommendations on 
Immunizations are available online at 
http://www.cdc.gov/mmwr/PDF/rr/rr5515.pdf.    
 
Volume 1, Issue 4 
Immunization Q & A 
Question:   
It has been several months, or even a few years, since a per-
son has had a dose of vaccine and has not  completed the 
vaccine series.  Does the series need to be restarted?  
 
Answer:   
Vaccination providers should administer vaccines as close to 
the recommended intervals as possible. However, longer than 
recommended intervals between doses do not reduce final 
antibody concentrations, although protection might not be 
attained until the recommended number of doses has been 
administered.  With the exception of oral typhoid vaccine, an 
interruption in the vaccination schedule does not require 
restarting the entire series of a vaccine or toxoid or 
addition of extra doses. 
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Childhood Immunization Schedule Revised in 2007 
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Summary of Changes to the  
Childhood Immunization Schedule 
The new 2007 Recommended Immunization Schedules were published January 
5, 2007.  The recommendations include several updates, new vaccines and a new 
format.  The following are updates to the childhood schedules: 
1. The new rotavirus vaccine (RotaTeq) is recommended in a 3-dose schedule 
at ages 2, 4, and 6 months. The first dose should be administered at ages 6 
weeks through 12 weeks with subsequent doses administered at 4-10 week 
intervals. Rotavirus vaccination should not be initiated for infants greater than 
12 weeks of age and should not be administered after 32 weeks of age.  
2. The influenza vaccine is now recommended for all children age 6-59 months.  
3. Varicella vaccine recommendations are updated. The first dose should be  
administered at age 12-15 months, and a newly recommended second dose 
should be administered at age 4-6 years.  
4. The new human papillomavirus vaccine (HPV) is recommended in a 3-dose schedule with the second and third doses  
administered 2 and 6 months after the first dose. Routine vaccination with HPV is recommended for females age 11-12 years; 
the vaccination series can be started in females as young as age 9 years; and a catch-up vaccination is recommended for 
females age 13-26 years who have not been vaccinated previously or who have not completed the full vaccine series.  
5. The main change to the format of the schedule is the division of the recommendation into two schedules: one schedule for 
persons age 0-6 years and another for persons age 7-18 years. Special populations are represented with purple bars; the 11-
12 years assessment is emphasized with the bold, capitalized fonts in the title of that column. Rota, HPV, and varicella  
vaccines are incorporated in the catch-up immunization schedule.  
If you have questions regarding vaccines or schedules please contact Terri Thornton or Bridget Konz at 1-800-831-6293 (ext. 2 
and 7 respectively).   
News You Can Use 
Useful Web Sites for  
Immunization Providers 
 
Centers for Disease Control and Prevention  
National Immunization Program    
www.cdc.gov/nip   
 
Iowa Immunization Program 
www.idph.state.ia.us/adper/immunization.asp 
 
The Immunization Action Coalition  
www.immunize.org  
 
Children’s Hospital of Philadelphia    
www.vaccine.chop.edu  
 
American Academy of Pediatrics   
www.aap.org        
 
 
2007  
Immunization  
Schedule  
 
2007 Recommended  
Immunization Schedules for children and adults are in-
cluded with this newsletter.     
Non-laminated schedules are available at no cost from the 
CDC Web site under “Recommended Vaccination/  
Immunization Schedules”: www.cdc.gov/nip/default.htm.   
If you would like additional laminated schedules they can 
be ordered for a nominal fee through the Immunization 
Action Coalition at: http://www.immunize.org/ 
New 2007 Immunization Schedules   
3 
Summary of Changes to the Adult Immunization Schedule 
Changes in the adult schedule since last publication are more numerous than the childhood schedule.  The adult schedule is also 
divided into two schedules; one by age and one by medical conditions/indications.  The key changes in the adult schedule include 
the following:  
1. The broken red line has been deleted on the age-based schedule.  Vaccination of persons with specific risk factors is now 
shown only with purple bars. 
2. Human papillomavirus (HPV) vaccine has been added to the 
age-based schedule, with a yellow bar indicating that the  
vaccine is recommended for women less than 26 years of age. 
3. Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine has 
been added to the age-based schedule, with a hatched yellow 
bar indicating that Tdap is a one-time, one-dose recommenda-
tion for persons less than 64 years of age. 
4. The purple bar for varicella vaccine has been shortened in  
anticipation of the recommendation for the use of zoster  
vaccine in persons greater than 60 years of age. 
5. A new column has been added to the medical/other indications 
schedule to clarify indications for hepatitis A and B vaccines. The indications “chronic liver disease” and “recipients of clotting 
factor concentrates” have been removed from the previous schedule and combined into a new column. The column has a 
yellow bar for hepatitis A and B vaccines, clarifying that these vaccines are recommended for all persons with these medical 
indications. 
6. HPV vaccine has been added to the medical/other indications schedule, with a yellow bar to indicate the vaccine is  
recommended for women less than 26 years of age with all indications except pregnancy. 
7. Tdap was added to the medical/other indications schedule, with a hatched yellow bar to indicate that Tdap is a one-time, one-
dose recommendation for all indications except pregnancy. 
8. Several of the footnotes (numbers 1,2,3,4,5 and 9) have been reworded or updated.   
If you have questions regarding vaccines or schedules please contact Terri Thornton or Bridget Konz at 1-800-831-6293 (ext. 2 
and 7 respectively).   
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Adult Immunization Schedule Revised in 2007 
Free Education Opportunities  
The CDC National Immunization Program is presenting a live net conference program titled 
“Current Issues in Immunization.” These one hour programs are designed to provide up-
to-date information on immunization by combining an online visual presentation with  
simultaneous audio via telephone conference call and a live question and answer session.   
These presentations are scheduled 4 times per year. Specific topics will be announced prior 
to each presentation. 
Remaining 2007 Schedule:  April 12, 2007, July 12, 2007, October 11 , 2007 
For more information about this net conference, and links to archived sessions, visit 
http://www.cdc.gov/nip/ed/ciinc/ 
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  HPV Implementation and VFC 
Quadrivalent Human Papillomavirus Vaccine (HPV) was included in the Iowa VFC Program for females 9 through 18 years of age 
effective February 1, 2007.  This table is intended as a quick reference that can be cut out and posted in your clinic.  If you have 
questions regarding the HPV vaccine, please contact Terri Thornton at 1-800-831-6293, ext. 2.  For questions regarding the VFC 
Program, please contact Tina Patterson at 1-800-831-6293, ext. 4. 
VFC Eligible Groups  VFC eligible females 9 through 18 years of age. 
Recommended Schedule for 
Quadrivalent HPV Vaccine 
  
A 3-dose series for the quadrivalent HPV vaccine is routinely recommended for females 11 through 12 years of 
age with the following schedule:    
1st dose:   Initial dose 
2nd dose:  2 months after the first dose 
3rd dose:      6 months after the first dose 
HPV vaccine can be administered at the same visit when other age appropriate vaccines are provided, such as 
Tdap, Td and MCV4. 
Minimum Intervals for 
Quadrivalent HPV Vaccine 
Administration Intervals 
Minimum Age  9 years  
Dose 1 to 2  4 weeks 
Dose 2 to 3 12 weeks 
VFC Catch-up Vaccination Catch-up vaccination is recommended for females 13-18 years of age who have not been previously vaccinated 
or who have not completed the full series. 
Interrupted Vaccine Schedules 
  
If the quadrivalent HPV vaccine schedule is interrupted, the vaccine series does not need to be restarted.  
If the series is interrupted after the first dose, the second dose should be given as soon as possible separated by 
an interval of at least 4 weeks.  The second and third doses should be separated by an interval of at least 12 
weeks. If only the third dose is delayed, it should be administered as soon as possible. 
Recommended Dosage Each dose of quadrivalent HPV vaccine is 0.5mL, administered intramuscularly.  Refer to product package insert. 
Vaccine Storage and Handling Store refrigerated at 2 to 8oC (35 to 46oF).  Do not freeze. Protect from light. 
Special Situations 
  
Quadrivalent HPV vaccine can be given to females who have an equivocal or abnormal Pap test, a positive Hy-
brid Capture II ® high risk test, or genital warts.  Vaccine recipients should be advised that data from clinical trials 
do not indicate the vaccine will have any therapeutic effect on existing Pap test abnormalities, HPV infection or 
genital warts.  Vaccination of these females would provide protection against infection with vaccine HPV types 
not already acquired. 
Immunocompromised Persons  HPV vaccine is not a live vaccine and can be administered to persons who are immunocompromised as a result 
of disease or medication; however, the immune response to the vaccine might be less than that in persons who 
are immunocompetent. 
Vaccination During Pregnancy 
  
Quadrivalent HPV vaccine is not recommended for use in pregnancy. The vaccine has not been causally 
associated with adverse outcomes of pregnancy or adverse events to the developing fetus. However, data on 
vaccination in pregnancy are limited. Until further information is available, initiation of the vaccine series should 
be delayed until after completion of the pregnancy. If a woman is found to be pregnant after initiating the vaccina-
tion series, completion of the 3-dose regimen should be delayed until after completion of the pregnancy. If a 
vaccine dose has been administered during pregnancy, there is no indication for any intervention. A vaccine in 
pregnancy registry has been established; patients and health-care providers are encouraged to report any expo-
sure to quadrivalent HPV vaccine during pregnancy by calling Merck at (800) 986-8999. 
Lactating Women Lactating women can receive HPV vaccine. 
Precautions and Contraindica-
tions 
  
Acute illness: Quadrivalent HPV vaccine can be administered to persons with minor acute illnesses (e.g., diar-
rhea or mild upper respiratory track infections, with or without fever).  Vaccination of persons with moderate or 
severe acute illnesses should be deferred until after the illness improves. 
Immediate hypersensitivity or allergy to vaccine components: Quadrivalent HPV vaccine is contraindicated 
for persons with a history of immediate hypersensitivity to yeast or to any vaccine component.  (Despite a theo-
retic risk for allergic reaction to vaccination in persons with allergy to baker’s yeast, no adverse reactions have 
been documented after vaccination of persons with a history of yeast allergy.) 
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MMRV and Varicella Vaccine 
Orders Status in IRIS 
V accine for Children Program orders for MMRV and varicella vaccines are shipped directly 
from Merck, the vaccine manufacturer.  
 In IRIS, the procedure to process  
vaccine orders distributed directly by 
the manufacture requires IDPH to 
“deny” the order in IRIS and then place 
the order in another system.  IRIS does 
not communicate directly with vaccine 
manufacturers; subsequently IDPH 
must manually submit an order on the 
provider’s behalf to the manufacturer.   
When viewing the “VFC Order  
Receiving” column for your order, the 
screen will display “order denied” and a 
lot number will not be listed.  This,  
however, may be confusing as the  
order may not have actually been  
denied – “scrolling right” will give you 
the complete story of your order.  
To determine the status of MMRV and 
varicella orders, users will need to 
scroll to the right side of the page to 
view the “Item Shipment/Adjustment 
Reason” column.  This column will con-
tain additional information regarding the 
order.   
If the order was placed with the  
manufacturer, “approved – submitted to 
manufacturer” will be displayed.  If this 
order was denied additional information 
will be displayed regarding the reason.   
Please remember to “scroll right” to get 
the complete information on your MMRV 
or varicella vaccine orders.   
If you have questions, please contact 
Janean Iddings at 515-281-7787 or  
1-800-831-6293 ext. 5 or the IRIS help 
desk at 1-800-374-3958. 
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The Iowa Immunization Program has  
pre-ordered a copy of the revised 10th  
Edition of Epidemiology and Prevention of 
Vaccine-Preventable Diseases 
(affectionately known as the “Pink Book” 
for the color of the cover) for each VFC  
provider in Iowa.   
This book is a staple in any clinic or  
practice providing immunizations.  It  
includes detailed information on each  
vaccine preventable disease as well as 
standard general recommendations and 
resources for patients.   
If you would like to order additional copies 
of the Pink Book; the 10th edition is  
expected to be available in March 2007.  
The cost is $29.00 each.  Ordering infor-
mation, as well as the full text of the book 
are available online at: 
http://www.cdc.gov/nip/publications/pink/de
fault.htm#Order 
Statewide Immunization      
Conference:  
Immunize for a Better Life  
The Iowa Immunization Conference titled  “Immunize for a Better Life” will be held 
June 7, 2007 at the Hy-Vee Conference Center in West Des Moines.   
Registration information is available through the Training Resources Web page: 
http://www.trainingresources.org/  or by calling 515-309-3315. 
Conference topics will include communicating with parents; infant, adolescent and adult 
immunizations; the burden of influenza disease; and vaccine storage and handling.   
Scheduled speakers include: William Atkinson, MD, MPH, Centers for Disease Control 
and Prevention; Paul Offit, MD, Children’s Hospital of Philadelphia; Patricia Quinlisk, 
MD, MPH, Iowa Department of Public Health; Patricia Stinchfield, RN, MS, CPNP, 
Hospitals and Clinics of St. Paul, MN; Jean Thomas, Family Medicine Specialists, PC. 
Pink 
Books! 
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• Social marketing and health 
communication 
• Formative and evaluation research 
• Materials development  
Free teleconferences and webcasts 
featuring immunization and coalition 
experts. 
Low-cost skills-building workshops 
at national and regional immunization 
conferences. 
Bi-weekly email newsletters alerting 
you to new immunization resources, 
upcoming events and technical 
assistance opportunities. 
Access to a moderated listserv, 
where you can share experiences and 
discuss issues of mutual concern with 
other coalitions. 
Do you belong to an immunization 
coalition or are you thinking of starting 
one? Does your coalition need help with 
strategic planning or evaluation?  Would 
you like to connect with other coalitions 
around the country?   
If yes, the Immunization Coalition 
Technical Assistance Network (IZTA) is 
for you!  IZTA is a growing community of 
new and seasoned immunization coalition 
members from across the United States.  
Membership in the Network is FREE and 
has many benefits: 
Customized, one-on-one technical 
assistance for your coalition in:  
• Coalition start-up and management 
• Strategic planning  
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National Infant 
Immunization Week 
National Immunization Week is April 21-28, 2007. 
Plan to celebrate National Infant Immunization Week in your 
clinic or health  
department.   
The following CDC Web page will 
soon display resources and ideas for 
how to promote this important week in 
Immunizations.  
http://www.cdc.gov/nip/events/niiw/ 
WELCOME! 
The Immunization Program is happy to announce that Kim Tichy, BS, CHES has joined our program as 
the IRIS Coordinator. Kim comes to the Immunization Program from the Bureau of Family Health where 
she worked in the Healthy Child Care Iowa program.   
We are excited to have her join our team and hope you will welcome her.  Kim’s phone number is  (515) 
281-4288 and her e-mail is ktichy@idph.state.ia.us.   For the IRIS help desk please call  
(515) 281-4258 or 1-800-374-3958.  
Vaccine Management  
Resource 
Recommendations for Storage and Handling of Selected 
Biologicals has been revised and published in January 2007.   
This booklet outlines the details of storing and handling of all 
vaccines.  Information includes shipping requirements, condi-
tion upon arrival, storage requirements, shelf life, instructions 
for use, shelf live after opening, and special instructions.   
This booklet is available from the CDC Web page:    
http://www.cdc.gov/nip/publications/vac_mgt_book.htm 
Kim Tichy  
The Immunization Coalitions Technical Assistance Network 
Valuable online resources, such as an 
event planning toolkit, e-tutorials and  
promising practices. 
Multiple individuals from the same 
coalition can join IZTA – There is no limit!  
Our members include staff of health 
departments, community-based 
organizations, pharmaceutical companies 
and universities, as well as health 
providers and pharmacists. 
Visit www.izta.org to register and explore 
our online resources.  You can also email 
us at izta@aed.org.   
IZTA is managed by The Academy for 
Educational Development in Washington, 
DC, under a cooperative agreement from 
the Centers for Disease Control and 
Prevention.  
